Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
暂无分享,去创建一个
Steven G Potkin | Nunzio Pomara | Brian R Ott | S. Potkin | J. Olin | N. Pomara | E. Peskind | B. Ott | Stephen M Graham | Elaine R Peskind | Scott McDonald | Jason T Olin | S. Graham | S. McDonald
[1] M. Mega,et al. The Neuropsychiatric Inventory , 1994, Neurology.
[2] G. Wilcock,et al. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) , 2002, International clinical psychopharmacology.
[3] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[4] R. Katzman.,et al. Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.
[5] J. Morris,et al. Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .
[6] B. Winblad,et al. Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.
[7] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[8] Pierre N Tariot,et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.
[9] Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.
[10] S H Ferris,et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.
[11] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[12] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[13] Rachelle Doody,et al. Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.
[14] K. Davis,et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.
[15] R. Ihl,et al. Alzheimer's Disease Assessment Scale: Reliability and Validity in a Multicenter Clinical Trial , 1997, International Psychogeriatrics.
[16] C. Parsons,et al. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.
[17] M. Sano,et al. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.
[18] D. Selkoe. The molecular pathology of Alzheimer's disease , 1991, Neuron.
[19] D. Bennett,et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.
[20] J. Peña-Casanova. Alzheimer's Disease Assessment Scale–Cognitive in Clinical Practice , 1997, International Psychogeriatrics.
[21] P. Doraiswamy,et al. Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil Experience , 1999, Journal of geriatric psychiatry and neurology.